Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant610 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03982134 | PDR001 + Panobinostat for Melanoma and NSCLC | withdrawn | Phase 1 | 0 | Muhammad FurqanOTHER | 0 | Oct 4, 2019 | clinicaltrials |
| NCT02387307 | A Study of rSIFN-co in Subjects With Advanced Solid Tumors(rSIFN-01) | completed | Phase 1 | 42 | Sichuan Huiyang Life Science and Technology CorporationINDUSTRY | 1 | Sep 27, 2019 | clinicaltrials |
| NCT02711345 | A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers. | terminated | Phase 1 | 65 | Novartis PharmaceuticalsINDUSTRY | 6 | Sep 19, 2019 | clinicaltrials |
| NCT03007823 | High-activity Natural Killer Immunotherapy for Small Metastases of Melanoma | completed | Phase 1 / Phase 2 | 20 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02045368 | Study of Insulin-like Growth Factor (IGF)-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R | completed | Phase 1 | 92 | IGF Oncology, LLCINDUSTRY | 1 | Aug 22, 2019 | clinicaltrials |
| NCT00571116 | Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy | terminated | Phase 1 | 9 | University of California, IrvineOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT03391050 | A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma | terminated | Phase 1 / Phase 2 | 3 | Aprea TherapeuticsINDUSTRY | 1 | Jul 31, 2019 | clinicaltrials |
| NCT01271803 | A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma | completed | Phase 1 | 131 | Hoffmann-La RocheINDUSTRY | 2 | Jul 29, 2019 | clinicaltrials |
| NCT01639911 | Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors | completed | Phase 1 | 28 | University of Illinois at ChicagoOTHER | 1 | Jul 22, 2019 | clinicaltrials |
| NCT02891616 | 18F-FLT PET Imaging in Patients With Advanced Melanoma | terminated | Phase 1 | 4 | Washington University School of MedicineOTHER | 1 | Jul 17, 2019 | clinicaltrials |
| NCT03111901 | Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer(UVA-AM-002) | withdrawn | Phase 1 / Phase 2 | 0 | William Grosh, MDOTHER | 1 | Jul 12, 2019 | clinicaltrials |
| NCT01996202 | A Pilot Study of Ipilumimab and Radiation in Poor Prognosis Melanoma | completed | Phase 1 | 24 | Duke UniversityOTHER | 1 | Jul 5, 2019 | clinicaltrials |
| NCT00438009 | A Safety Study of Two Intratumoural Doses of Coxsackievirus Type A21 in Melanoma Patients (PSX-X03) | completed | Phase 1 | 9 | ViralyticsINDUSTRY | 1 | Jul 1, 2019 | clinicaltrials |
| NCT00636558 | Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers (PSX-X04)(PSX-X04) | completed | Phase 1 | 8 | ViralyticsINDUSTRY | 1 | Jul 1, 2019 | clinicaltrials |
| NCT00235482 | Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma (PXS-X02)(PXS-X02) | completed | Phase 1 | 3 | ViralyticsINDUSTRY | 1 | Jun 27, 2019 | clinicaltrials |
| NCT01137006 | An Open-Label, Dose-Escalation Study of IMC-20D7S In Participants With Malignant Melanoma | completed | Phase 1 | 27 | Eli Lilly and CompanyINDUSTRY | 1 | Jun 17, 2019 | clinicaltrials |
| NCT02153905 | T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Jun 17, 2019 | clinicaltrials |
| NCT00301067 | Phase I/II Study of High-Dose Calcitriol Plus Temodar for Patients With Metastatic Melanoma | completed | Phase 1 / Phase 2 | 20 | Northwestern UniversityOTHER | 1 | Jun 4, 2019 | clinicaltrials |
| NCT02300935 | Study of Trametinib and Nab-paclitaxel in Patients With Melanoma | withdrawn | Phase 1 | 0 | SCRI Development Innovations, LLCOTHER | 1 | May 30, 2019 | clinicaltrials |
| NCT01910181 | A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma | completed | Phase 1 | 46 | Hoffmann-La RocheINDUSTRY | 1 | May 29, 2019 | clinicaltrials |
| NCT01017185 | Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions | completed | Phase 1 | 28 | Takara Bio Inc.INDUSTRY | 1 | May 23, 2019 | clinicaltrials |
| NCT01603212 | Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor | completed | Phase 1 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | May 21, 2019 | clinicaltrials |
| NCT02027961 | Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone | completed | Phase 1 | 68 | MedImmune LLCINDUSTRY | 4 | May 17, 2019 | clinicaltrials |
| NCT03472027 | Phase I Study of BCD-145 (Anti-CTLA-4) in Patients With Unresectable/Metastatic Melanoma | completed | Phase 1 | 15 | BiocadINDUSTRY | 1 | May 9, 2019 | clinicaltrials |
| NCT03903458 | Tinostamustine and Nivolumab in Advanced Melanoma(ENIgMA) | unknown | Phase 1 | 21 | Markus JoergerOTHER | 1 | Apr 8, 2019 | clinicaltrials |
| NCT03353402 | Fecal Microbiota Transplantation (FMT) in Metastatic Melanoma Patients Who Failed Immunotherapy | unknown | Phase 1 | 40 | Sheba Medical CenterOTHER_GOV | 1 | Apr 3, 2019 | clinicaltrials |
| NCT02117362 | Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma | completed | Phase 1 | 8 | Providence Health & ServicesOTHER | 1 | Mar 21, 2019 | clinicaltrials |
| NCT01191034 | Peptide Vaccination Associated With Tumoral Immunomodulation in Patients With Advanced Metastatic Melanoma | terminated | Phase 1 / Phase 2 | 2 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Mar 12, 2019 | clinicaltrials |
| NCT01723813 | Peptide Vaccinations Plus GM-CT-01 in Melanoma | terminated | Phase 1 / Phase 2 | 6 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Mar 12, 2019 | clinicaltrials |
| NCT00365937 | Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides | terminated | Phase 1 / Phase 2 | 19 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Mar 6, 2019 | clinicaltrials |
| NCT00223899 | A Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma | completed | Phase 1 | 26 | VicalINDUSTRY | 1 | Feb 27, 2019 | clinicaltrials |
| NCT00470015 | Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma | completed | Phase 1 | 20 | Mayo ClinicOTHER | 1 | Feb 19, 2019 | clinicaltrials |
| NCT00844064 | Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2 | completed | Phase 1 | 62 | Isarna Therapeutics GmbHINDUSTRY | 1 | Feb 15, 2019 | clinicaltrials |
| NCT02068079 | A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma | withdrawn | Phase 1 | 0 | Duke UniversityOTHER | 1 | Jan 30, 2019 | clinicaltrials |
| NCT02941744 | A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases(ipniv) | completed | Phase 1 / Phase 2 | 56 | Universitair Ziekenhuis BrusselOTHER | 1 | Jan 24, 2019 | clinicaltrials |
| NCT01350401 | Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma | terminated | Phase 1 / Phase 2 | 4 | AdaptimmuneINDUSTRY | 1 | Jan 10, 2019 | clinicaltrials |
| NCT01457131 | Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer | terminated | Phase 1 | 2 | National Cancer Institute (NCI)NIH | 1 | Jan 8, 2019 | clinicaltrials |
| NCT00929019 | Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients | terminated | Phase 1 / Phase 2 | 23 | Radboud University Medical CenterOTHER | 1 | Dec 7, 2018 | clinicaltrials |
| NCT02327390 | Ex Vivo-Activated Lymph Node Lymphocytes in Treating Patients With Stage IIIC-IV Melanoma | terminated | Phase 1 | 3 | Case Comprehensive Cancer CenterOTHER | 1 | Dec 6, 2018 | clinicaltrials |
| NCT00527657 | Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients | completed | Phase 1 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 14, 2018 | clinicaltrials |
| NCT00791271 | Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion | terminated | Phase 1 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 9, 2018 | clinicaltrials |
| NCT02654821 | Study With T-cel Receptor Gene Therapy in Metastatic Melanoma(TCR) | unknown | Phase 1 / Phase 2 | 12 | The Netherlands Cancer InstituteOTHER | 1 | Nov 2, 2018 | clinicaltrials |
| NCT00568763 | Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryotherapy in Treating Patients With Stage IV Melanoma | completed | Phase 1 | 11 | Mayo ClinicOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT02115243 | Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma | completed | Phase 1 | 4 | Duke UniversityOTHER | 1 | Oct 29, 2018 | clinicaltrials |
| NCT01986426 | LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab | completed | Phase 1 | 80 | Lytix Biopharma ASINDUSTRY | 5 | Oct 3, 2018 | clinicaltrials |
| NCT01876641 | Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib(ML28604) | terminated | Phase 1 | 18 | Mohammed M MilhemOTHER | 1 | Sep 19, 2018 | clinicaltrials |
| NCT02447939 | Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma | withdrawn | Phase 1 | 0 | GlaxoSmithKlineINDUSTRY | 0 | Sep 14, 2018 | clinicaltrials |
| NCT01215500 | Dose Escalation of Hypofractionated Radiation Therapy in Patients With Metastatic Cancer | completed | Phase 1 | 63 | University of ChicagoOTHER | 1 | Sep 12, 2018 | clinicaltrials |
| NCT00039091 | Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer | terminated | Phase 1 | 26 | National Cancer Institute (NCI)NIH | 1 | Sep 5, 2018 | clinicaltrials |
| NCT02650635 | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors | terminated | Phase 1 | 4 | Mayo ClinicOTHER | 1 | Sep 5, 2018 | clinicaltrials |
Data updated 24 days agoSource updated Oct 4, 2019source: clinicaltrials